No Prescription |
 |
 | ||
|
ABAMUNE Ziagen |
|
| ||
No Prescription » Prescription Drugs 1 » ABAMUNE Ziagen Abacavir is used in combination with other medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS). Abacavir is in a class of antiviral medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by slowing the spread of HIV infection in the body. Abacavir is not a cure and may not decrease the number of HIV-related illnesses. Abacavir does not prevent the spread of HIV to other people.Abacavir comes as a tablet and a solution (liquid) to take by mouth. It is usually taken twice a day with or without food. To help you remember to take abacavir take it around the same time every day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take abacavir exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.Continue to take abacavir even if you feel well. Do not stop taking abacavir without talking to your doctor. Buy ABAMUNE Ziagen and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About ABAMUNE Ziagen: Product Type: Prescription Drugs 1 ABAMUNE ( Ziagen Generic Abacavir Sulphate ) ABAMUNE (Ziagen Generic Abacavir Sulphate) Ziagen Generic Abacavir Sulphate 300MG 30 Tablets 300mg 2 x 30 Tablets 300mg 3 x 30 Tablets Ziagen Generic Abacavir Sulphate ABAMUNE
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
